RT journal article
T1 Serum microRNAs targeting ACE2 and RAB14 genes distinguish asymptomatic from critical COVID-19 patients
A1 Calderón Domínguez, María
A1 Trejo Gutiérrez, Eva Lucía
A1 González Rovira, Almudena
A1 Beltrán Camacho, Lucía
A1 Rojas Torres, Marta
A1 Eslava Alcón, Sara
A1 Sánchez Morillo, Daniel
A1 Calderón-Domínguez, Juan
A1 Martinez‑Nicolás, Mª Pilar
A1 Gonzalez-Beitia, Estibaliz
A1 Nieto-Martín, Mª Dolores
A1 Trujillo-Soto, Teresa
A1 Rodríguez Iglesias, Manuel Antonio
A1 Moreno, Juan A.
A1 Moreno Luna, Rafael
A1 Durán Ruiz, María del Carmen
A2 BiomedicinaBiotecnología y Salud Pública
A2 Ingeniería en AutomáticaElectrónica, Arquitectura y Redes de Computadores
AB Despite the extraordinary advances achieved to beat COVID-19 disease, many questions remain unsolved, including the mechanisms of action of SARS-CoV-2 and which factors determine why individuals respond so differently to the viral infection. Herein, we performed an in silico analysis to identify host microRNA targeting ACE2, TMPRSS2, and/or RAB14, all genes known to participate in viral entry and replication. Next, the levels of six microRNA candidates previously linked to viral and respiratory-related pathologies were measured in the serum of COVID-19-negative controls (n = 16), IgG-positive COVID-19 asymptomatic individuals (n = 16), and critical COVID-19 patients (n = 17). Four of the peripheral micro-RNAs analyzed (hsa-miR-32-5p, hsa-miR-98-3p, hsa-miR-423-3p, and hsa-miR-1246) were upregulated in COVID-19 critical patients compared with COVID-19-negative controls. Moreover, hsa-miR-32-5p and hsa-miR-1246 levels were also altered in critical versus asymptomatic individuals. Furthermore, these microRNA target genes were related to viral infection, inflammatory response, and coagulation-related processes. In conclusion, SARS-CoV-2 promotes the alteration of microRNAs targeting the expression of key proteins for viral entry and replication, and these changes are associated with disease severity. The microRNAs identified could be taken as potential biomarkers of COVID-19 progression as well as candidates for future therapeutic approaches against this disease.
PB ELSEVIER
SN 2162-2531
YR 2022
FD 2022-09
LK http://hdl.handle.net/10498/27709
UL http://hdl.handle.net/10498/27709
LA eng
DS Repositorio Institucional de la Universidad de Cádiz
RD 07-nov-2026